DIMENSION THERAPEUTICS
Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, ... Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.
DIMENSION THERAPEUTICS
Industry:
Biotechnology Genetics Medical Therapeutics
Founded:
2013-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Total Employee:
1+
Status:
Active
Contact:
617-401-0011
Email Addresses:
[email protected]
Total Funding:
124.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Domain Not Resolving IPv6 Cloudflare Google Cloud Cloudflare Hosting Cloudflare Network Error Logging Cloudflare DNS Cloudflare SSL
Similar Organizations
Corvidia
Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Neos Therapeutics
Neos Therapeutics is an oral drug delivery company developing controlled time-release technologies.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Larimar Therapeutics
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
RA Capital Management
RA Capital Management investment in Series B - Dimension Therapeutics
Jennison Associates
Jennison Associates investment in Series B - Dimension Therapeutics
New Leaf Venture Partners
New Leaf Venture Partners investment in Series B - Dimension Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series B - Dimension Therapeutics
Partner Fund Management
Partner Fund Management investment in Series B - Dimension Therapeutics
Tourbillon Global Ventures
Tourbillon Global Ventures investment in Series B - Dimension Therapeutics
F-Prime Capital
F-Prime Capital investment in Series B - Dimension Therapeutics
OrbiMed
OrbiMed investment in Series B - Dimension Therapeutics
Fidelity Biosciences
Fidelity Biosciences investment in Series A - Dimension Therapeutics
OrbiMed
OrbiMed investment in Series A - Dimension Therapeutics
More informations about "Dimension Therapeutics"
Ultragenyx to Acquire Dimension Therapeutics
Oct 3, 2017 About Dimension Therapeutics, Inc. Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leader in discovering and developing new therapeutic products for people living with …See details»
Dimension Therapeutics - PitchBook
Dimension Therapeutics General Information Description. Developer of gene therapies for rare diseases. The company develops novel treatment and focus on advancing its platform of gene therapy programs in rare diseases through …See details»
Dimension Therapeutics, Inc. - Drug pipelines, Patents, Clinical …
Explore Dimension Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 17 news, and 3 literature, Drug:DTX-501, DTX-601. ... The statistics for drugs …See details»
Dimension Therapeutics - Company Profile - Tracxn
Nov 19, 2024 Dimension Therapeutics ranks 104th among 792 active competitors. 268 of its competitors are funded while 215 have exited. Overall, Dimension Therapeutics and its …See details»
Organization | Dimension Therapeutics - Purdue University
Organization Overview. First Clinical Trial. 2015 NCT02618915. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Dimension Therapeutics, Inc. Active Ingredients. …See details»
Dimension Therapeutics acquired by Ultragenyx Pharmaceutical
Nov 7, 2017 Dimension Therapeutics Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases. Acquiring Organization: Ultragenyx …See details»
Dimension Therapeutics (USA) Funding: $124.5M - Medical Startups
Nov 26, 2024 Dimension Therapeutics is developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. Dimension’s lead programs address significant …See details»
Dimension Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Dimension Therapeutics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Dimension Therapeutics Inc - Company Profile and News
Dimension Therapeutics, Inc. operates as a biotechnology company. The Company focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders.See details»
Dimension Therapeutics - Funding, Financials, Valuation & Investors
Dimension Therapeutics is registered under the ticker NASDAQ:DMTX . Their stock opened with $13.00 in its Oct 22, 2015 IPO. Stock Symbol NASDAQ:DMTX ; IPO Share Price $13.00; IPO …See details»
Dimension Therapeutics - Crustdata Company Profile, Funding …
Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene …See details»
Dimension Therapeutics - VentureRadar
Similar Companies: Spark Therapeutics USA Publicly Traded Spark Therapeutics is using adeno-associated viral (AAV) vectors to advance research programs against strategically selected …See details»
Dimension Therapeutics Overview | SignalHire Company Profile
Dimension Therapeutics is a private company that has been in the industry for 10 years. The company currently specializes in the Biotechnology, Biotechnology areas. ... Organization …See details»
Dimension Therapeutics, Inc. - Cruelty Free Investing
Dimension Therapeutics, Inc. engages in the provision of medical development. Its activities include discoveries and development of therapeutic products for people living with rare …See details»
Dimension Therapeutics, Inc. (DMTX) - Yahoo Finance Canada
View Top Holdings and Key Holding Information for Dimension Therapeutics, Inc. (DMTX).See details»
Dimension Therapeutics - VentureRadar
Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. The company's team comprises biotech industry veterans and thought leaders …See details»
Dimension Therapeutics - Contacts, Employees, Board Members, …
Organization. Dimension Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Employee Profiles 3. Number of Board Member and Advisor …See details»
Organization | Dimension Therapeutics
Organization Overview. First Clinical Trial. 2015 NCT02618915. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Dimension Therapeutics, Inc. Active Ingredients. …See details»
Dimension leaps into gene therapy action with $252M Bayer deal, …
Jun 23, 2014 Over the past 7 months, Dimension Therapeutics has been moving fast to take its place among a new wave of gene therapy developers looking to revolutionize the way some …See details»